EP2167026B1 - Cosmetic composition for treatment of canities - Google Patents

Cosmetic composition for treatment of canities Download PDF

Info

Publication number
EP2167026B1
EP2167026B1 EP08760661.2A EP08760661A EP2167026B1 EP 2167026 B1 EP2167026 B1 EP 2167026B1 EP 08760661 A EP08760661 A EP 08760661A EP 2167026 B1 EP2167026 B1 EP 2167026B1
Authority
EP
European Patent Office
Prior art keywords
khellin
hair
canities
use according
mask
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP08760661.2A
Other languages
German (de)
French (fr)
Other versions
EP2167026A1 (en
Inventor
Giammaria Giuliani
Anna Benedusi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Giuliani SpA
Original Assignee
Giuliani SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani SpA filed Critical Giuliani SpA
Priority to EP08760661.2A priority Critical patent/EP2167026B1/en
Publication of EP2167026A1 publication Critical patent/EP2167026A1/en
Application granted granted Critical
Publication of EP2167026B1 publication Critical patent/EP2167026B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/12Preparations containing hair conditioners

Definitions

  • the present invention concerns the topical use of Khellin to reduce the amount of grey and white hair due to canities.
  • Khellin, or 4,9-dimethoxy-7-methyl-5H-furo[3,2-g][1]benzopyran-5-one is a derivative of coumarin which is known for its vasodilatory properties.
  • EP680761 (Indena ) relates to topical formulations based on khellin for cicatrizing the skin by means of its peripheral vasokinetic activity.
  • EP693278 (Indena ) relates to formulations against hair loss based on khellin, combined with unsaturated fatty acids, again utilizing its peripheral vasokinetic activity.
  • Khellin has also been studied for therapy of the skin disorder known as vitiligo, characterized by non-pigmented skin patches.
  • NB narrow band
  • UVB ultraviolet rays
  • khellin for topical use is effective in reducing the amount of white hair due to canities without having to combine it with other agents such as UV light.
  • the current invention presents a composition for cosmetic use able to reduce the amount of white hair due to canities, characterized by comprising khellin as the active principle and excipients that render it suitable for topical use on hair.
  • khellin can be present as the only active principle in the composition or in combination with one or more additional active principles, chosen from phenylalanine, ornithine, catechin, quercetin, copper salts such as copper gluconate.
  • composition of the invention can be prepared in the form of a possibly liposomal hair treatment mask, or shampoo, or lotion, or conditioner, or mousse.
  • khellin is comprised in a quantity between 0.2 and 1.8% w/v.
  • the quantity of each of the components is expressed as percentage weight per volume, % w/v, or, in the case of lotions, as weight in grams per 100 ml.
  • Example 1 Liposomal hair mask
  • INGREDIENTS (INCI names) g in 100 ml 1 Citric acid 0.04-0.052 2 Disodium EDTA 0.03-0.06 3 Alcohol 15-20 4 PEG-40 Hydrogenated castor oil 0.5-3 5 Tween 20 0.5-1.0 6 Per10 7 Khellin 0.5-1.8 8 Water q.s. to 100 ml
  • Example 5 Specific shampoo for problems of the scalp
  • INGREDIENTS (INCI names) % w/v 1 Disodium EDTA 0.10-0.30 2 Polyquaternium-10 0.10-0.30 3 Polyquaternium-55 0.1-0.50 4 Citric acid 0.60-0.80 5 Potassium undecylenoyl hydrolyzed wheat protein 3.6000 6 Sodium lauroyl sarcosinate 1.5000 7 Cocamide mipa 1.0-3.0 8 Disodium laureth sulfosuccinate 1.0-5.0 9 Disodium capryloyl glutamate 0.4-1.0 10 Zinc coceth sulfate 1.0-8.0 11 PEG-200 hydrogenated glyceryl palmate 0.5-3.0 12 PEG-7 glyceryl cocoate 0.5-2.0 13 Laureth-2 0.05-2.0 14 PEG-40 hydrogenated castor oil 0.2-1.0 15 perfume q.s. 16 Phenyl trimethicone 0.05-3.0 17 Silicone quaternium-15 0.005-1.0 18 Laureth-4
  • Example 7 Liposomal mask for hair
  • INGREDIENTS (INCI names) g in 100 ml 1 Citric acid 0.04-0.052 2 Disodium EDTA 0.03-0.06 3 Alcohol 15-20 4 PEG-40 Hydrogenated castor oil 0.5-3 5 Tween 20 0.5-1.0 6 perfume 0.10 7 Khellin 0.5-1.8 8 Ornithine 0.2-0.5 Water q.s. to 100 ml
  • Example 11 Specific shampoo for problems of the scalp
  • INGREDIENTS (INCI names) % w/v 1 Disodium EDTA 0.10-0.30 2 Polyquaternium-10 0.10-0.30 3 Polyquaternium-55 0.1-0.50 4 Citric acid 0.60-0.80 5 Ornithine 0.10-0.05 6 Potassium undecylenoyl hydrolyzed wheat protein 3.6000 7 Sodium lauroyl sarcosinate 1.5000 8 Cocamide mipa 1.0-3.0 9 Phenylalanine 0.10-0.50 10 Disodium laureth sulfosuccinate 1.0-5.0 11 Disodium capryloyl glutamate 0.4-1.0 12 Zinc coceth sulfate 1.0-8.0 13 Peg-200 hydrogenated glyceryl palmate 0.5-3.0 14 Peg-7 glyceryl cocoate 0.5-2.0 15 Laureth-2 0.05-2.0 16 Peg-40 hydrogenated castor oil 0.2-1.0 17 perfume q.s.
  • a double-blind clinical study was carried out using a mask 1-A in accordance with the invention comprising 1.5% w/v khellin in combination with phenylalanine, ornithine, copper gluconate and excipients suitable for topical application to hair, compared with the use of a placebo formulation 1-B, i.e. a similar mask base for hair but without the active principle.
  • the subjects in active group A used a gentle shampoo 2-A containing 1% khellin and formulated with liposomes, to be used twice weekly for four weeks.
  • non-active group B used a normal gentle shampoo 2-B as a comparison, i.e. without active principles.
  • shampoo 2-A was shown to be effective in maintaining the action of mask 1-A treatment.
  • composition of the invention is mainly indicated for anti-ageing cosmetic use, for preventing and treating canities and hence ageing of the hair.
  • composition of the invention Following topical application of the composition of the invention to hair, an increase in the anagen phase of the hair growth cycle (compared to the baseline) as well as an increase in hair shaft diameter in subjects affected by androgenetic alopecia was generally also apparent.
  • composition of the invention is particularly indicated for the treatment of canities associated with androgenetic alopecia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)

Description

  • The present invention concerns the topical use of Khellin to reduce the amount of grey and white hair due to canities.
  • Khellin, or 4,9-dimethoxy-7-methyl-5H-furo[3,2-g][1]benzopyran-5-one is a derivative of coumarin which is known for its vasodilatory properties.
  • US4412071 (UpJohn ) describes khellin analogues indicated as anti-arteriosclerosis agents.
  • EP680761 (Indena ) relates to topical formulations based on khellin for cicatrizing the skin by means of its peripheral vasokinetic activity.
  • EP693278 (Indena ) relates to formulations against hair loss based on khellin, combined with unsaturated fatty acids, again utilizing its peripheral vasokinetic activity.
  • Khellin has also been studied for therapy of the skin disorder known as vitiligo, characterized by non-pigmented skin patches. In this regard, research has shown how the use of NB (narrow band) UVB is particularly effective in the treatment of said disease. Procaccini (Ann. Ital. Dermatol. Clin. Sper., 1993, 47, 4) reports that applying khellin topically would not in itself have a specific repigmentation action against vitiligo, any effective repigmentation action being essentially due to induction by UV rays.
  • According to the present invention, it has been surprisingly found that khellin for topical use is effective in reducing the amount of white hair due to canities without having to combine it with other agents such as UV light.
  • Principally to achieve this activity but also other advantages which will be described henceforth, the current invention presents a composition for cosmetic use able to reduce the amount of white hair due to canities, characterized by comprising khellin as the active principle and excipients that render it suitable for topical use on hair.
  • According to the present invention, khellin can be present as the only active principle in the composition or in combination with one or more additional active principles, chosen from phenylalanine, ornithine, catechin, quercetin, copper salts such as copper gluconate.
  • The composition of the invention can be prepared in the form of a possibly liposomal hair treatment mask, or shampoo, or lotion, or conditioner, or mousse. Preferably, in a composition according to the invention khellin is comprised in a quantity between 0.2 and 1.8% w/v. With the aim of better understanding the characteristics of the invention, nonlimiting examples of its practical implementation are described in the following.
  • The quantity of each of the components is expressed as percentage weight per volume, % w/v, or, in the case of lotions, as weight in grams per 100 ml.
  • In the examples, where indicated, the INCI names of the components are given in accordance with the International Nomenclature of Cosmetic Ingredients.
  • Example 1 - Liposomal hair mask
  • Components % w/v
    1 Glycerin 3.00
    5 Tween 20 1.00
    6 Cremophor 0.30
    7 Aristoflex 0.70
    8 Phenonip 0.98
    9 Copper gluconate 0.10
    11 Cromollient SCE 3.00
    13 Cremophor 0.60
    14 Khellin 1.0-1.5
    15 Phosal 75 SA 3.00
    16 Parfum 0.60
    17 Patent blue (0.2% solution) 0.30
    18 Demineralized water q.s. to 100 ml
  • Example 2 - Hair mask
  • Components % w/v
    1 Corn starch 1.5
    2 BC 2366 2.5
    3 Disodium EDTA 0.2
    4 Cetrimonium chloride 4
    5 Salcare SC 92 2
    6 Glycerin 4
    7 Nexbase 2004 2
    8 Fancol VB 1.5
    9 BC 2262 0.5
    10 Lanette O 1.5
    11 Palm oil 0.8
    12 Brij 721 1
    13 Khellin 0.5-1.5
    14 Crodazosoft DBQ 8
    15 Cremophor RH 40 0.2
    16 Tween 20 0.9
    17 Glycerin 3.0
    18 Incroquat behenyl tms 0.5-0.7
    19 Cromollient SCE 0.6
    20 Tween 20 0.1
    21 Parfum 0.5
    22 Phenonip 1
    23 Water q.s. to 100 ml
  • Example 3 - Shampoo
  • Components % w/v
    1 EDTA 0.20
    2 Polyquaternium-10 0.40
    3 Sodium Lauroyl Sarcosinate 9.00
    4 Magnesium laureth sulfate (75%) and Disodium laureth sulfosuccinate (25%) 38.00
    5 Potassium Undecylenoyl Hydrolyzed wheat protein 1.00
    6 PEG-40 Hydrogenated Castor Oil 0.50
    7 Polysorbate 20 1.00
    8 Cremophor RH 40 0.2
    9 Tween 20 0.9
    10 Glycerin 3.0
    11 cromollient SCE 0.6
    12 Prolipid 151 0.6
    13 khellin 0.5-1.5
    14 tween 20 0.3
    15 cremophor RH40 6
    16 Phenyltrimethicone & Silicone Quaternium-15 0.50
    17 Silicone quaternium-15 & C11-15 Pareth-5 & C11-15 Pareth-9 0.80
    18 Parfum 12144 0.60
    19 BHA 0.01
    20 Crodasilk liquid 1.00
    21 Lauryl Methyl Gluceth-10 Hydroxypropyldimonium Chloride 0.50
    22 Wheat (triticum vulgare) gliadins 1.00
    23 Dore Gold AS232 0.05
    24 Glycol Distearate, Laureth-7, Sodium Cocoamphoacetate, Cocamidopropyl Betaine and Sodium Laureth Sulfate 6.00
    25 PEG-90 Glyceryl Isostearate (and) Laureth-2 1.20
    26 PEG-120 Methyl Glucose dioleate 1.20
    27 KCl 0.60
    28 phenoxyethanol, methylparaben, butylparaben, ethylparaben, propylparaben 0.98
    29 citric acid 0.50
    30 Demineralized water q.s. to 100.00
  • Example 4 - Hair lotion
  • INGREDIENTS (INCI names) g in 100 ml
    1 Citric acid 0.04-0.052
    2 Disodium EDTA 0.03-0.06
    3 Alcohol 15-20
    4 PEG-40 Hydrogenated castor oil 0.5-3
    5 Tween 20 0.5-1.0
    6 Parfum 0.10
    7 Khellin 0.5-1.8
    8 Water q.s. to 100 ml
  • Example 5 - Specific shampoo for problems of the scalp
  • INGREDIENTS (INCI names) % w/v
    1 Disodium EDTA 0.10-0.30
    2 Polyquaternium-10 0.10-0.30
    3 Polyquaternium-55 0.1-0.50
    4 Citric acid 0.60-0.80
    5 Potassium undecylenoyl hydrolyzed wheat protein 3.6000
    6 Sodium lauroyl sarcosinate 1.5000
    7 Cocamide mipa 1.0-3.0
    8 Disodium laureth sulfosuccinate 1.0-5.0
    9 Disodium capryloyl glutamate 0.4-1.0
    10 Zinc coceth sulfate 1.0-8.0
    11 PEG-200 hydrogenated glyceryl palmate 0.5-3.0
    12 PEG-7 glyceryl cocoate 0.5-2.0
    13 Laureth-2 0.05-2.0
    14 PEG-40 hydrogenated castor oil 0.2-1.0
    15 Parfum q.s.
    16 Phenyl trimethicone 0.05-3.0
    17 Silicone quaternium-15 0.005-1.0
    18 Laureth-4 0.010-0.5
    19 Khellin 0.5-1.8
    20 Water q.s. to 100 ml
  • Example 6 - Hair mousse
  • Ingredients (INCI names) % w/v
    1 Alcohol denat. 12.0-15.0
    4 Ethoxydiglycol 1.0-3.0
    5 Sodium lauryl sulfate 0.5-2.0
    6 Sodium hydroxide 0.01-0.06
    7 Citric acid 0.01-0.06
    8 Peg-40 hydrogenated castor oil 0.30-0.60
    9 Parfum q.s
    10 Tocotrienols 0.01-0.05
    11 Potassium undecylenoyl hydrolyzed wheat protein 0.050-1.0
    12 Zinc coceth sulfate 0.050-0.1
    13 Polyquaternium-16 0.020
    14 Khellin 0.2-0.5
    15 Water q.s. to 100ml
  • Example 7 - Liposomal mask for hair
  • Components % w/v
    1 Glycerin 3.00
    Ornithine 0.20-0.9
    3 Phenylalanine 0.20-0.60
    4 Pycnogenol 0.10-0.50
    5 Tween 20 1.00
    6 Cremophor 0.30
    7 Aristoflex 0.70
    8 Phenonip 0.98
    9 Copper gluconate 0.10
    10 Catechin 0.05-0.1
    11 Cromollient SCE 3.00
    12 Quercetin 0.01-0.1
    13 Cremophor 0.60
    14 Khellin 0.3-1.3
    15 Phosal 75 SA 3.00
    16 Parfum 0.60
    17 Patent blue (0.2% solution) 0.30
    18 Demineralized water q.s. to 100 ml
  • Example 8 - Hair mask
  • Components % w/v
    1 Corn starch 1.5
    2 Ornithine 0.8-1.20
    3 Phenylalanine 0.1-0.40
    4 Copper gluconate 0.05-0.1
    5 BC 2366 2.5
    6 Disodium EDTA 0.2
    7 Cetrimonium chloride 4
    8 Salcare SC 92 2
    9 Glycerin 4
    10 Nexbase 2004 2
    11 Ceramide A2 0.2-0.5
    12 Fancol VB 1.5
    13 BC 2262 0.5
    14 Lanette O 1.5
    15 Palm Oil 0.8
    16 Brij 721 1
    17 Khellin 0.5-1.5
    18 Crodazosoft DBQ 8
    19 Catechin 0.025-0.07
    20 Cremophor RH 40 0.2
    21 Tween 20 0.9
    22 Glycerin 3.0
    23 Panthenol 0.1-0.25
    24 Nanocream 0.8-1.2
    25 Incroquat behenyl tms 0.5-0.7
    26 Quercetin 0.01-0.005
    27 Cromollient SCE 0.6
    28 Tween 20 0.1
    29 Parfum 0.5
    30 Phenonip 1
    31 Water q.s. to 100 ml
  • Example 9 - Shampoo
  • Components % w/v
    1 EDTA 0.20
    2 Ornithine 0.5-1.2
    3 Phenylalanine 0.2-0.6
    4 Copper gluconate 0.08-0.12
    5 Polyquaternium-10 0.40
    6 Sodium Lauroyl Sarcosinate 9.00
    7 Magnesium laureth sulfate (75%) and Disodium laureth sulfosuccinate (25%) 38.00
    8 Potassium Undecylenoyl Hydrolyzed wheat protein 1.00
    9 PEG40 Hydrogenated Castor Oil 0.50
    10 Polysorbate 20 1.00
    11 Catechin 0.025-0.07
    12 Pycnogenol 0.05-0.15
    13 Cremophor RH 40 0.2
    14 Tween 20 0.9
    15 glycerin 3.0
    16 panthenol 0.2
    17 nanocream 10
    18 Quercetin 0.01-0.005
    19 cromollient SCE 0.6
    20 Prolipid 151 0.6
    21 khellin 0.5-1.5
    22 tween 20 0.3
    23 cremophor RH40 6
    24 Phenyltrimethicone & Silicone Quaternium-15 0.50
    25 Silicone quaternium-15 & C11-15 Pareth-5 & C11-15 Pareth-9 0.80
    26 Parfum 12144 0.60
    27 BHA 0.01
    28 Crodasilk liquid 1.00
    29 Lauryl Methyl Gluceth-10 Hydroxypropyldimonium Chloride 0.50
    30 Wheat (triticum vulgare) gliadins 1.00
    31 Hairspheres Biogenina 0.2-0.3
    32 Dore Gold AS 232 0.05
    33 Glycol Distearate, Laureth-7, Sodium Cocoamphoacetate, Cocamidopropyl Betaine and Sodium Laureth Sulfate 6.00
    34 PEG-90 Glyceryl Isostearate (and) Laureth-2 1.20
    35 PEG-120 Methyl Glucose dioleate 1.20
    36 KCI 0.60
    37 phenoxyethanol, methylparaben, butylparaben, ethylparaben, propylparaben 0.98
    38 citric acid 0.50
    39 Demineralized water q.s. to 100.00 ml
  • Example 10 - Hair lotion
  • INGREDIENTS (INCI names) g in 100 ml
    1 Citric acid 0.04-0.052
    2 Disodium EDTA 0.03-0.06
    3 Alcohol 15-20
    4 PEG-40 Hydrogenated castor oil 0.5-3
    5 Tween 20 0.5-1.0
    6 Parfum 0.10
    7 Khellin 0.5-1.8
    8 Ornithine 0.2-0.5
    Water q.s. to 100 ml
  • Example 11 - Specific shampoo for problems of the scalp
  • INGREDIENTS (INCI names) % w/v
    1 Disodium EDTA 0.10-0.30
    2 Polyquaternium-10 0.10-0.30
    3 Polyquaternium-55 0.1-0.50
    4 Citric acid 0.60-0.80
    5 Ornithine 0.10-0.05
    6 Potassium undecylenoyl hydrolyzed wheat protein 3.6000
    7 Sodium lauroyl sarcosinate 1.5000
    8 Cocamide mipa 1.0-3.0
    9 Phenylalanine 0.10-0.50
    10 Disodium laureth sulfosuccinate 1.0-5.0
    11 Disodium capryloyl glutamate 0.4-1.0
    12 Zinc coceth sulfate 1.0-8.0
    13 Peg-200 hydrogenated glyceryl palmate 0.5-3.0
    14 Peg-7 glyceryl cocoate 0.5-2.0
    15 Laureth-2 0.05-2.0
    16 Peg-40 hydrogenated castor oil 0.2-1.0
    17 Parfum q.s.
    18 Phenyl trimethicone 0.05-3.0
    19 Silicone quaternium-15 0.005-1.0
    20 Laureth-4 0.010-0.5
    21 Khellin 0.5-1.8
    22 Catechin 0.025-0.07
    23 Quercetin 0.01-0.005
    24 Water q.s. to 100 ml
  • Example 12 - Hair mousse
  • Ingredients (INCI names) % w/v
    1 Alcohol denat. 12.0-15.0
    2 Ornithine 0.050-0.20
    3 Salicylic acid 0.05-0.02
    4 Ethoxydiglycol 1.0-3.0
    6 Sodium lauryl sulfate 0.5-2.0
    7 Sodium hydroxide 0.01-0.06
    8 Citric acid 0.01-0.06
    9 Panthenol 0.200
    10 Glutathione 0.10-0.5
    11 P-hydroxyanisole 0.05-0.12
    12 Potassium azeloyl diglycinate 0.090
    13 Phytic acid 0.01-0.03
    14 Peg-40 hydrogenated castor oil 0.30-0.60
    15 Parfum q.b
    16 Tocotrienols 0.01-0.05
    17 Potassium undecylenoyl hydrolyzed wheat protein 0.050-1.0
    18 Zinc coceth sulfate 0.050-0.1
    19 Polyquaternium-16 0.020
    20 Phenylalanine 0.2-0.6
    21 Khellin 0.2-0.5
    22 Water q.s to 100 ml
  • With the aim of better understanding the advantages of the invention, the following describes a clinical study carried out on healthy volunteers.
  • CLINICAL STUDY
  • An assessment was made of the effectiveness of a topical treatment for reducing the amount of white hair due to canities of two compositions in accordance with the invention, i.e.
    1. 1) hair mask formulated with liposomes
    2. 2) shampoo formulated with liposomes
  • A double-blind clinical study was carried out using a mask 1-A in accordance with the invention comprising 1.5% w/v khellin in combination with phenylalanine, ornithine, copper gluconate and excipients suitable for topical application to hair, compared with the use of a placebo formulation 1-B, i.e. a similar mask base for hair but without the active principle.
  • 50 volunteers, comprising 40 women and 10 men between 35 and 55 years of age, and healthy according to specific inclusion and exclusion criteria, including the exclusion of immunological pathologies and of systemic drug consumption were treated as follows.
  • 1-A and 1-B were applied three times a week for eight weeks to each subject. At the end of the treatment, each subject was evaluated by:
    • dermatological examination
    • macro photograph (digital)
    • epiluminescence (Molemax II)
    • Reflectance Confocal Microscopy (RCM) using a Lucid confocal microscope.
  • In 65% of the subjects treated with mask 1-A a 20-30% reduction in grey/white hair was found compared with a 2% reduction in grey/white hair in subjects treated with mask 1-B, with reduction of up to a maximum of 5%, p = 0.05.
  • Additionally, of those treated with mask 1-A, an increase in the anagen phase of the hair growth cycle (compared to the baseline) as well as an increase in the hair shaft diameter were found in subjects affected by androgenetic alopecia.
  • After having completed the assessment on the treatment with mask 1), the subjects in active group A used a gentle shampoo 2-A containing 1% khellin and formulated with liposomes, to be used twice weekly for four weeks.
  • The subjects in non-active group B used a normal gentle shampoo 2-B as a comparison, i.e. without active principles.
  • At the end of the four weeks, the assessments were repeated on all subjects.
    • in group A it was found that the results obtained with mask 1-A application were maintained.
    • in group B with free shampoo 2-B a slight increase in grey hair was noted, but was not statistically significant compared to the baseline of the non-active group. In conclusion, application of mask 1-A with the active principle of the invention has demonstrated a capacity to increase the number of repigmented hairs even though repigmentation of the whole head of hair was not observed.
  • Application of shampoo 2-A was shown to be effective in maintaining the action of mask 1-A treatment.
  • No systemic or localized side effects were noted on use of the products at the end of the reported study.
  • The composition of the invention is mainly indicated for anti-ageing cosmetic use, for preventing and treating canities and hence ageing of the hair.
  • It is particularly indicated for the treatment of greying hair and hair in the initial stages of canities for reducing its progression.
  • Following topical application of the composition of the invention to hair, an increase in the anagen phase of the hair growth cycle (compared to the baseline) as well as an increase in hair shaft diameter in subjects affected by androgenetic alopecia was generally also apparent.
  • For this reason, the composition of the invention is particularly indicated for the treatment of canities associated with androgenetic alopecia.

Claims (7)

  1. Use of khellin as a cosmetic for reducing the amount of grey or white hair due to canities.
  2. Use of khellin for reducing the amount of grey or white hair due to canities, while at the same time producing an increase in the anagen phase and hair shaft diameter in subjects affected by androgenetic alopecia.
  3. Use according to the preceding claims wherein khellin is formulated in a composition comprising excipients suitable for topical use on hair.
  4. Use according to the preceding claims wherein khellin is used in combination with one or more active compounds chosen from: phenylalanine, ornithine, catechin, quercetin, copper salts.
  5. Use according to the preceding claims wherein khellin is prepared in the form of a mask for hair treatment, or shampoo, or lotion, or conditioner, or mousse.
  6. Use according to claim 5 wherein the said form contains liposomes.
  7. Use according to the preceding claims wherein khellin is prepared in a composition in a quantity from 0.2 to 1.8% w/v.
EP08760661.2A 2007-06-11 2008-06-06 Cosmetic composition for treatment of canities Active EP2167026B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08760661.2A EP2167026B1 (en) 2007-06-11 2008-06-06 Cosmetic composition for treatment of canities

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07425366A EP2005942A1 (en) 2007-06-11 2007-06-11 Cosmetic composition for treatment of canities
EP08760661.2A EP2167026B1 (en) 2007-06-11 2008-06-06 Cosmetic composition for treatment of canities
PCT/EP2008/057091 WO2008151994A1 (en) 2007-06-11 2008-06-06 Cosmetic composition for treatment of canities

Publications (2)

Publication Number Publication Date
EP2167026A1 EP2167026A1 (en) 2010-03-31
EP2167026B1 true EP2167026B1 (en) 2015-12-09

Family

ID=38738811

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07425366A Withdrawn EP2005942A1 (en) 2007-06-11 2007-06-11 Cosmetic composition for treatment of canities
EP08760661.2A Active EP2167026B1 (en) 2007-06-11 2008-06-06 Cosmetic composition for treatment of canities

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP07425366A Withdrawn EP2005942A1 (en) 2007-06-11 2007-06-11 Cosmetic composition for treatment of canities

Country Status (2)

Country Link
EP (2) EP2005942A1 (en)
WO (1) WO2008151994A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022478A1 (en) * 2007-08-07 2009-02-11 KPSS-Kao Professional Salon Services GmbH Conditioning composition for hair
DE102009044974A1 (en) * 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Use of dihydroquercetin and at least one amino acid to positively influence the natural pigmentation process
FR2980691B1 (en) 2011-09-30 2014-03-14 Galderma Sa WASHING COMPOSITION
DE102011086636A1 (en) * 2011-11-18 2013-05-23 Henkel Ag & Co. Kgaa Hair care products containing amino acids and cationic silicones
WO2013179098A1 (en) * 2012-06-01 2013-12-05 Laboratori Farmaceutici Krymi S.P.A. Association of potassium caproyl tyrosine, l-phenylalanine and taurine and use thereof to prevent and slow down white hair
PL2919747T3 (en) 2012-11-13 2019-03-29 Galderma S.A. Bpo wash gel composition
WO2014076136A1 (en) 2012-11-13 2014-05-22 Galderma S.A. Bpo wash emulsion composition
FR3022778A1 (en) * 2014-06-30 2016-01-01 Oreal USE OF A COMBINATION OF ORNITHINE AND CITRIC ACID TO LIMIT HAIR LOSS
WO2018225482A1 (en) * 2017-06-07 2018-12-13 花王株式会社 Ammonia metabolism promoter
IT201700080737A1 (en) * 2017-07-17 2019-01-17 Marilena Cammarota Topical liposphere preparation to induce the repigmentation of skin areas affected by vitiligo.
FR3132842A1 (en) * 2022-02-21 2023-08-25 L'oreal compositions and methods for treating keratinous materials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85688A1 (en) * 1984-12-18 1986-07-17 Oreal COSMETIC ACCELERATING TANNING BASED ON FUROCHROMONES
IT1269634B (en) * 1994-05-06 1997-04-08 Indena Spa TOPICAL MEDICATION WITH CICATRIZING ACTIVITY
IT1278997B1 (en) * 1994-07-19 1997-12-02 Indena Spa COMBINATIONS OF VASOACTIVE SUBSTANCES WITH FATTY ACIDS TO FIGHT HAIR LOSS
FR2782920B1 (en) * 1998-09-07 2000-10-06 Oreal USE OF AT LEAST ONE ROSACEA EXTRACT OF THE GENUS SANGUISORBA OFFICINALIS TO PROMOTE PIGMENTATION OF THE SKIN AND / OR HAIR
DE19853425A1 (en) * 1998-11-19 2000-05-25 Martin Roecken Topical composition containing khellin or its derivatives, useful for phototherapy of psoriasis and eczema, has low mitogenic potential
DE10150445A1 (en) * 2001-10-12 2003-04-17 Beiersdorf Ag Use of purine or pyrimidine compounds without oxidants in intensifying natural hair colors or in stimulating melanogenesis in human hair, e.g. in masking gray hair
WO2003039596A1 (en) * 2001-11-09 2003-05-15 Qlt Inc. Photodynamic therapy for the treatment of hair loss

Also Published As

Publication number Publication date
EP2005942A1 (en) 2008-12-24
EP2167026A1 (en) 2010-03-31
WO2008151994A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
EP2167026B1 (en) Cosmetic composition for treatment of canities
ES2398478T5 (en) Stable soluble salts of phenylbenzimidazolsulfonic acid from pH 6.0 to less than 6.8
US20060013845A1 (en) Oxygenated personal care products
JP2011516524A (en) Novel compositions and uses thereof
KR101516074B1 (en) Compositions comprising Polydatin and Tranexamic acid for whitening
BR112021015309A2 (en) ANTIMICROBIAL ACTIVITY OF FATTY ACID ESTERS AND COMBINATIONS THEREOF
US20240197605A1 (en) Composition for Treating Hair, Scalp and Skin
US11918666B2 (en) Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment
US10363207B2 (en) All-in-one skin-brightening formulations
KR20160143793A (en) Compositions and methods for reducing oxidative stress
KR101511252B1 (en) Compositions comprising Atractyloides japonica rhizome extract and Tranexamic acid for whitening
US9066880B2 (en) Use of dihydrodehydrodiisoeugenol and preparations comprising dihydrodehydrodiisoeugenol
KR100738434B1 (en) Cosmetic composition containing pyrrolidinyl diaminopyrimidine oxide
KR102246477B1 (en) Methods of reducing signs of skin aging
JPH03112912A (en) Cosmetic composition
EP2862852B1 (en) Urea derivatives for the protection of stem cells
KR101493483B1 (en) Hair and scalp protective composition for hair dyeing
ES2367134T3 (en) USE OF AN OXIALQUILENATED SORBITAN ESTER AS A CALMING LEATHER CALMING AGENT.
KR100441059B1 (en) Composition for improving conditions of scalp and hair
KR20160133007A (en) Topical composition including a combination of extracts for reducing signs of skin aging
ES2631191B1 (en) COMPOSITION FOR SOLAR PROTECTION AND REPAIR OF THE SKIN THROUGH PROTECTIVE COMPLEXES
JPH03178922A (en) Dandruff-suppressing agent composition
WO2024056566A1 (en) Use of thioethylamine composition for skin rejuvenation and improved synergistic effect when combined with an organic acid and/or azabenzene-4-carboxamide
EP3922236A1 (en) Compositions for topical treatment of acquired melanosis of the skin
JP2024517403A (en) Hair treatment compositions and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20120704

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150624

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 764240

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008041561

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20151209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 764240

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160310

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160409

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160411

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008041561

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

26N No opposition filed

Effective date: 20160912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008041561

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160606

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170103

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160606

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151209